Search
Sodium glycerophosphate
go.drugbank.com/drugs/DB09561ApprovedIt is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667].
Mixtures: SmofKabiven Low Osmo peripher Emulsion zur Infusion, OLICLINOMEL N4-550 E EMULSION FOR INFUSIONPretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigational[L8048,L8066] Unlike other therapeutic regimens for the treatment of resistant TB, which may take 18 months or longer and may not be effective, the pretomanid-containing regimen allows for a more efficacious … It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.
Levofloxacin
go.drugbank.com/drugs/DB01137ApprovedInvestigational[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663] … carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin[A190663] and remains stereochemically stable following administration (i.e. it does not
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high
Gemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalMarketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered … On September 1 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule
Tyrosine-protein phosphatase non-receptor type 11
go.drugbank.com/bio_entities/BE0001071TargetHumansActs downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus (PubMed:10655584, PubMed:14739280, PubMed:18559669, PubMed:18829466, PubMed:26742...
Polypeptides: Tyrosine-protein phosphatase non-receptor type 11Non-selective voltage-gated ion channel VDAC1
go.drugbank.com/bio_entities/BE0002468TargetHumansNon-selective voltage-gated ion channel that mediates the transport of anions and cations through the mitochondrion outer membrane and plasma membrane (PubMed:10661876, PubMed:11845315, PubMed:18755977
Polypeptides: Non-selective voltage-gated ion channel VDAC1Tyrosine-protein phosphatase non-receptor type 2
go.drugbank.com/bio_entities/BE0012706TargetHumansNon-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. … Also dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3 and STAT6 either in the nucleus or the cytoplasm.
Polypeptides: Tyrosine-protein phosphatase non-receptor type 2Pilocarpine
go.drugbank.com/drugs/DB01085ApprovedInvestigational[A262036] Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated intraocular pressure and glaucoma. The usage of glaucoma by pilocarpine dates back to 1875. … [A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors.
Rosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalRosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. … Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele.